X4-logo.png
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
December 12, 2022 08:30 ET | X4 Pharmaceuticals
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an...
X4-logo.png
X4 Pharmaceuticals Prices $65.0 Million Public Offering
December 07, 2022 08:43 ET | X4 Pharmaceuticals
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...
X4-logo.png
X4 Pharmaceuticals Announces Proposed Public Offering
December 06, 2022 18:26 ET | X4 Pharmaceuticals
BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...
X4-logo.png
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
November 29, 2022 16:01 ET | X4 Pharmaceuticals
4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute...
X4-logo.png
X4 Pharmaceuticals to Present at Stifel Healthcare Conference
November 08, 2022 08:00 ET | X4 Pharmaceuticals
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022 16:05 ET | X4 Pharmaceuticals
BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...
X4-logo.png
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022 06:05 ET | X4 Pharmaceuticals
Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the...
X4-logo.png
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
October 26, 2022 08:00 ET | X4 Pharmaceuticals
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc....
X4-logo.png
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
October 20, 2022 08:00 ET | X4 Pharmaceuticals
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of...
X4-logo.png
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
September 27, 2022 07:50 ET | X4 Pharmaceuticals
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across...